Filing Flows › Comparisons › VNDA vs SDGR
Vanda Pharmaceuticals vs Schrodinger: VNDA and SDGR compared
Vanda Pharmaceuticals is the larger company: $69.8M of revenue in its latest quarter (Q3 2026) against $64.5M for Schrodinger (Q3 2026). Vanda Pharmaceuticals is growing faster (+24% against +19% a year earlier). Vanda Pharmaceuticals is more profitable, with an operating margin of -33.7% against -40.5%.
Where the money goes: VNDA and SDGR
Vanda Pharmaceuticals (VNDA) · Q3 2026
Vanda Pharmaceuticals, Q3 2026: revenue $69.8M (+24% year over year), operating margin -33.7%, net loss $22.6M, operating cash flow −$28.4M. The chart follows the revenue to costs, profit and cash.
Schrodinger (SDGR) · Q3 2026
Schrodinger, Q3 2026: revenue $64.5M (+19% year over year), operating margin -40.5%, net loss $37.7M, operating cash flow −$47.6M. The chart follows the revenue to costs, profit and cash.
| Vanda Pharmaceuticals (VNDA) | Schrodinger (SDGR) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $69.8M | $64.5M |
| Revenue growth, Y/Y | +24% | +19% |
| Operating margin | -33.7% | -40.5% |
| Net earnings | −$22.6M | −$37.7M |
| Net margin | -32.3% | -58.5% |
| Operating cash flow | −$28.4M | −$47.6M |
| Market value | — | $2.0B |
| Analysts’ mean target | — | $29.57 |
Where the revenue comes from
Vanda Pharmaceuticals
- Fanapt®: $38.8M (56%)
- HETLIOZ® net product sales: $21.7M (31%)
- PONVORY® net product sales: $7.7M (11%)
- NEREUSTM: $1.6M (2%)
Schrodinger
- Software products and services: $38.2M (59%)
- Drug discovery: $24.2M (38%)
- Contribution: $2.2M (3%)
Questions
Which is bigger, Vanda Pharmaceuticals or Schrodinger?
Vanda Pharmaceuticals is the larger company: $69.8M of revenue in its latest quarter (Q3 2026) against $64.5M for Schrodinger (Q3 2026).
Is Vanda Pharmaceuticals or Schrodinger growing faster?
Vanda Pharmaceuticals is growing faster (+24% against +19% a year earlier).
Which is more profitable, Vanda Pharmaceuticals or Schrodinger?
Vanda Pharmaceuticals is more profitable, with an operating margin of -33.7% against -40.5%.
More: Vanda Pharmaceuticals earnings · how Vanda Pharmaceuticals makes money · Schrodinger earnings · how Schrodinger makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 29, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.